PASSAGE BIO INC (PASG:NASDAQ)
$5.82 0.22 (3.9286%)
Analysed PASSAGE BIO INC (PASG:NASDAQ) News Sources
Passage Bio to Participate in Chardan’s 9th Annual Genetic Medicines Conference
14-10-2025
yahoo.com
Passage Bio to Present at Guggenheim Securities 2nd Annual Healthcare Innovation Conference
05-11-2025
yahoo.com
Passage Bio Reports Third Quarter 2025 Financial Results and Provides Recent Business Highlights
10-11-2025
yahoo.com
Passage Bio to Participate in Upcoming Investor Conferences
19-02-2026
yahoo.com
Passage Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Recent Business Highlights
03-03-2026
yahoo.com
Passage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate Updates
20-04-2026
yahoo.com
Passage Bio Seen as Undervalued Despite FDA Setback, Oppenheimer Says
21-04-2026
yahoo.com
Passage Bio Faces Tougher FDA Road After Trial Shift, Wedbush Says
21-04-2026
yahoo.com
Sector Update: Health Care Stocks Softer Late Afternoon
21-04-2026
yahoo.com
Passage Bio Inc (PASG) Stock: Should You Buy the Dip For 125% Upside?
20-05-2026
yahoo.com
What is the current price of PASSAGE BIO INC (PASG:NASDAQ)?
The current price of PASSAGE BIO INC (PASG:NASDAQ) is $5.82.
PASSAGE BIO INC (PASG:NASDAQ) absolute price change since previous trading day?
The absolute price change of PASSAGE BIO INC (PASG:NASDAQ) since the previous trading day is $0.22.
PASSAGE BIO INC (PASG:NASDAQ) percentage price change since previous trading day?
The percentage price change of PASSAGE BIO INC (PASG:NASDAQ) since the previous trading day is 3.9286%.
What is the most recent average sentiment score for PASSAGE BIO INC (PASG:NASDAQ)?
The most recent average sentiment score for PASSAGE BIO INC (PASG:NASDAQ) is 74 out of 100.
What is the most recent average sentiment for PASSAGE BIO INC (PASG:NASDAQ)?
The most recent sentiment for PASSAGE BIO INC (PASG:NASDAQ) is .
SEC-8K** Filing Available For PASSAGE BIO INC (PASG:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.